Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik Tbk's EBIT per Share for the
three
months ended in Mar. 2026 was Rp1.88.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was Rp11.74.
During the past 12 months, the average EBIT per Share Growth Rate of PT Bundamedik Tbk was 27.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -20.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -23.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PT Bundamedik Tbk's EBIT per Share or its related term are showing as below:
ISX:BMHS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50.5 Med: -19.7 Max: 120.7
Current: -20.7
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of PT Bundamedik Tbk was 120.70% per year. The lowest was -50.50% per year. And the median was -19.70% per year.
ISX:BMHS's 3-Year EBIT Growth Rate is ranked worse than 87.6% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs ISX:BMHS: -20.70
PT Bundamedik Tbk (ISX:BMHS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PT Bundamedik Tbk EBIT per Share Related Terms
PT Bundamedik Tbk EBIT per Share Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp11.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a EBIT per Share of Rp11.74 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Bundamedik Tbk and its competitors. According to the industry distribution chart, PT Bundamedik Tbk ranks #459 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 87.6%.
Is PT Bundamedik Tbk's EBIT per Share too high?
PT Bundamedik Tbk's current EBIT per Share is Rp11.74. Based on the distribution chart, PT Bundamedik Tbk ranks #459 out of 524 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Bundamedik Tbk has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #459 out of 524 companies for EBIT per Share. This places PT Bundamedik Tbk in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current EBIT per Share is Rp11.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Possible Value Trap. The stock's GF Value™ is Rp308.86, compared to a current price of Rp180.00 — trading 41.7% below its estimated fair value. The current EBIT per Share is Rp11.74. PT Bundamedik Tbk's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current EBIT per Share is Rp11.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp180.00 is trading 41.7% below its estimated GF Value™ of Rp308.86.
GuruFocus considers PT Bundamedik Tbk to be Possible Value Trap.
Key valuation signals for ISX:BMHS:
EBIT per Share: Rp11.74
GF Value™: Rp308.86 vs. price of Rp180.00 (41.7% below fair value)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
61GF Score
Get the complete analysis for ISX:BMHS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
